Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

v3.5.0.2
Segment Reporting (Tables)
6 Months Ended
May 31, 2016
Segment Reporting [Abstract]  
Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax benefit (expense) and other comprehensive income for the three months and six months ended May 31, 2016:

 

     For the three months
ended May 31, 2016
    For the six months
ended May 31, 2016
 

Net revenue

    

Umbilical cord blood and cord tissue stem cell service

   $ 5,349,745      $ 10,370,204   

Prepacyte®-CB

     66,379        198,118   
  

 

 

   

 

 

 

Total net revenue

   $ 5,416,124      $ 10,568,322   
  

 

 

   

 

 

 

Cost of sales

    

Umbilical cord blood and cord tissue stem cell service

   $ 1,345,370      $ 2,590,393   

Prepacyte®-CB

     85,730        188,998   
  

 

 

   

 

 

 

Total cost of sales

   $ 1,431,100      $ 2,779,391   
  

 

 

   

 

 

 

Depreciation and amortization

    

Umbilical cord blood and cord tissue stem cell service

   $ 28,555      $ 57,233   

Prepacyte®-CB

     13,317        26,187   
  

 

 

   

 

 

 

Total depreciation and amortization

   $ 41,872      $ 83,420   
  

 

 

   

 

 

 

Operating income

    

Umbilical cord blood and cord tissue stem cell service

   $ 915,052      $ 1,056,069   

Prepacyte®-CB

     (32,668     (17,263
  

 

 

   

 

 

 

Total operating income

   $ 882,384      $ 1,038,806   
  

 

 

   

 

 

 

Interest expense

    

Umbilical cord blood and cord tissue stem cell service

   $ 335,589      $ 582,532   

Prepacyte®-CB

     7,874        22,265   
  

 

 

   

 

 

 

Total interest expense

   $ 343,463      $ 604,797   
  

 

 

   

 

 

 

The following table shows the assets by segment as of May 31, 2016 and November 30, 2015:

 

     As of May 31, 2016      As of November 30,
2015
 

Assets

     

Umbilical cord blood and cord tissue stem cell service

   $ 17,741,253       $ 16,697,621   

Prepacyte®-CB

     2,728,075         2,800,325   
  

 

 

    

 

 

 

Total assets

   $ 20,469,328       $ 19,497,946